Loading clinical trials...
Loading clinical trials...
A Phase 1 Study Evaluating A Second Generation Antisense Oligonucleotide (OGX 427) That Inhibits Heat Shock Protein 27 (Hsp27
Conditions
Interventions
OGX-427
Docetaxel
Locations
3
United States
Seattle Cancer Care Alliance
Seattle, Washington, United States
BC Cancer Agency
Vancouver, British Columbia, Canada
Juravinski Cancer Center
Hamilton, Ontario, Canada
Start Date
June 1, 2007
Primary Completion Date
June 1, 2011
Completion Date
October 1, 2011
Last Updated
January 18, 2016
NCT07159659
NCT07169851
NCT07213804
NCT00026884
NCT07481851
NCT06662786
Lead Sponsor
Achieve Life Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions